LivaNova (NASDAQ:LIVN) Updates FY 2026 Earnings Guidance

LivaNova (NASDAQ:LIVN) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.150-4.250 for the period, compared to the consensus earnings per share estimate of 3.900. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Analyst Ratings Changes

A number of analysts have commented on LIVN shares. Stifel Nicolaus lifted their target price on shares of LivaNova from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Wall Street Zen raised LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Mizuho upped their price objective on LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a research report on Monday, December 29th. Finally, Piper Sandler reissued an “overweight” rating and set a $85.00 price objective on shares of LivaNova in a research note on Thursday, February 19th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $71.11.

LivaNova Stock Up 1.0%

Shares of LIVN stock opened at $69.05 on Wednesday. LivaNova has a 52-week low of $32.48 and a 52-week high of $69.52. The stock has a market cap of $3.77 billion, a price-to-earnings ratio of -17.26 and a beta of 0.97. The firm’s 50-day moving average is $64.26 and its 200-day moving average is $58.73. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.12 and a current ratio of 1.33.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.80 by $0.06. LivaNova had a negative net margin of 16.12% and a positive return on equity of 15.98%. The firm had revenue of $360.90 million during the quarter, compared to analysts’ expectations of $354.31 million. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Sell-side analysts predict that LivaNova will post 2.85 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in LIVN. UMB Bank n.a. increased its stake in shares of LivaNova by 22.6% in the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after buying an additional 179 shares during the period. Parallel Advisors LLC grew its holdings in LivaNova by 28.8% during the 4th quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock worth $78,000 after acquiring an additional 283 shares during the period. California State Teachers Retirement System lifted its stake in shares of LivaNova by 0.9% in the 2nd quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock valued at $2,260,000 after purchasing an additional 458 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares during the period. Finally, State of Wyoming acquired a new stake in LivaNova in the second quarter valued at approximately $31,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.